Is your approach to managing immune related adverse events altered at all in light of COVID-19?

First of all, I wish to thank @Dr. First Last from Johns Hopkins/Sibley for his advice addressing this critical topic.

We are all witnessing a rapidly evolving crisis that none of us have been prepared for and it is the right thing to quickly consider as best as we can how the COVID-19 pandemic should impact our practices in the coming weeks/months, as to the best management of our cancer patients. We are all scrambling with many issues as to who does or does not need to be seen, treated, at what...

I appreciate the excellent response and community coming together to share knowledge. At the risk of overloading with resources and content, there is a podcast by the Uromigos group (group of Urologic Oncologists) that discuss this topic at the link below and a written section compiled by Dr. Doug Johnson from Vanderbilt on the hemonc.org webpage.

(1) Uromigos: Episode 11: COVID-19 and Immune Checkpoint Inhibitors for the Treatment of Cancer

(2) hemonc.org COVID-19 page